| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
2 companies
Dexcel Pharma Technologies Ltd. serves as a 10% Owner at ROIV and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 3 buys and 2 sells. Those positions are worth an estimated $3.7B at current prices.
Historically, Dexcel Pharma Technologies Ltd.'s trades have earned a strong insider score of 79/100 across 5 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +72.8%.
The biggest single holding is ROIV (~$3.7B) as 10% Owner. Net of sales, the recent Form 4 record there shows accumulation of 4,040,285 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2022 | ROIV Roivant Sciences Ltd. | 10% Owner | Buy | 4,000,000 | $5.00 | $20,000,000.00 | +4.0% | +48.5% | +70.1% | |
| Apr 25, 2022 | ROIV Roivant Sciences Ltd. | 10% Owner | Buy | 40,285 | $3.85 | $154,954.16 | - | +2.7% | +115.8% | |
| Jun 3, 2021 | PLX Protalix Biotherapeutics, Inc. | 10% Owner | Sell | 918,717 | $2.27 | $2,088,857.27 | -10.2% | -28.4% | -44.1% |